-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Halozyme Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2024.
- Halozyme Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was $137M, a 60.5% increase year-over-year.
- Halozyme Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was $444M, a 57.7% increase year-over-year.
- Halozyme Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $444M, a 57.7% increase from 2023.
- Halozyme Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $282M, a 39.3% increase from 2022.
- Halozyme Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $202M, a 49.8% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)